Skip to content
Clinical ResearchResearch compoundLimited evidence

Fasoracetam

Experimental racetam studied in ADHD; its effect in humans is not proven, and it is approved nowhere.

NootropicRacetamCholinergicMood SupportAcetylcholineGlutamateGABA
Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Pharmacology

ClassRacetam · Cholinergic · Mood Support
Primary targetGABA-B receptors (upregulation)
Targets3 receptor targets
EvidenceLimited evidence
Affected systemsAcetylcholineGlutamateGABA

Contents

DETAILED OVERVIEW

What is Fasoracetam?

Fasoracetam is an experimental racetam-type compound, originally developed in Japan. It is not approved as a medicine anywhere, and it has been studied for ADHD (attention-deficit hyperactivity disorder). It is banned in the United Kingdom, and elsewhere the legal status is uncertain when it is sold as a supplement.

It acts on certain receptors of glutamate, a brain messenger, increasing their number and activity. In ADHD studies in adolescents, early results looked promising, but the results of an expanded 2019 trial were mixed, so its effect in humans is not proven. Side effects can include headache, abdominal complaints and fatigue. It strengthens the effect of phenibut and of other substances acting on a similar calming system, and with longer use, strain on the liver and kidneys is a concern. It should be avoided in pregnancy and breastfeeding, because there are no safety data.

Mechanism

mGluR I/II/III up-regulation

Half-life

~5-8 h

Legal status

Investigational, clinical trials

Receptor profile

  • GABA-B receptorsStrong
  • mGluR (Groups I, II, III)Moderate
  • Choline uptakeModerate

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Headache, often from increased cholinergic activity (mitigated with a choline source such as CDP-choline)
  • Abdominal pain, diarrhea and nausea, mainly at doses above the nootropic range
  • Fatigue, lethargy
  • Irritability
  • Dizziness, mild lightheadedness, especially when starting use

Contraindications · 5

  • Pregnancy and breastfeeding: no safety data, should be avoided
  • Combined with phenibut or other GABA-B-active agents it potentiates their effect (GABA-B upregulation), caution required
  • Prolonged high-dose use may burden liver and kidney function, caution with long-term use
  • Clinical-trial-stage compound, not approved anywhere, long-term safety unknown
  • Not recommended under 18; those on medication or with serious medical conditions should seek medical advice first

Related Nootropics

Same therapeutic category

FAQ

FAQ

Fasoracetam is a compound from the racetam family, originally developed in Japan, that acts on certain brain signaling systems (glutamate receptors). Its most concrete, documented use case is ADHD: it went through clinical trials (Phase 2/3) for that purpose. Based on the source, it's best understood as a research/clinical-stage compound rather than a widely established, everyday supplement.

Telegram

Have a question about Fasoracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC10H16N2O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.